Real-time imaging and quantification of brain delivery of liposomes

• Published in: Pharmaceutical research Vol. 23; no. 11; pp. 2493 - 2504
• Main Authors: KRAUZE, Michal T, FORSAYETH, John, PARK, John W, BANKIEWICZ, Krystof S
• Format: Journal Article
• Language: English
• Published: New York, NY Springer 01.11.2006; Springer Nature B.V
• Subjects: Animals; Biological and medical sciences; Blood-Brain Barrier; Brain; Brain - metabolism; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Convection; Drug Delivery Systems; Drug therapy; Fluorescence; Gadolinium - administration & dosage; General pharmacology; Humans; Liposomes - metabolism; Magnetic Resonance Imaging; Measurement; Medical imaging; Medical sciences; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Drug; blood-brain barrier; Pharmaceutical technology; CED; convection-enhanced delivery; MR; MRI; Liposome; Blood brain barrier; Nuclear magnetic resonance imaging; Encephalon; Medical imagery; Pharmacokinetics; direct drug delivery
• ISSN: 0724-8741; 1573-904X
• DOI: 10.1007/s11095-006-9103-5

The surgical delivery of therapeutic agents into the parenchyma of the brain is problematic because it has been virtually impossible to know with any certainty where infused material is going, and how much to infuse. We have started to use liposomes loaded with Gadoteridol (GDL) as a tracer that allows us to follow infusions in real-time on magnetic resonance imaging (MRI). MRI allows precise tracking and measurement of liposomes loaded with markers and therapeutics. This review provides an overview of real-time delivery of liposomes to the central nervous system (CNS), and discusses the technical aspects of delivery, liposomes as colloidal systems of delivery, real-time distribution of liposomes in CNS, and quantification of liposome distribution. Our data suggests that real-time monitoring of liposomal drug infusion is likely to improve outcomes of clinical trials where convection-enhanced delivery (CED) is being used to target drugs to specific brain structures through limitation of systemic toxicity and reduction of side effects. This review is a summary of work done by our group over the past four years.